The cancer therapies market size in Europe is expected to grow by USD 34.71 bn from 2021 to 2026, progressing at a CAGR of 7.92%, according to Technavio. The report offers an up-to-date analysis as well as exact growth variance and the Y-O-Y growth rate.
Request a free sample report for additional highlights related to the market
Cancer Therapies Market in Europe 2022-2026: Scope
The cancer therapies market in Europe report covers the following areas:
- Cancer Therapies Market in Europe size
- Cancer Therapies Market in Europe trends
- Cancer Therapies Market in Europe industry analysis
Cancer Therapies Market in Europe 2022-2026: Drivers and Challenges
The increased prevalence of cancer is one of the key drivers supporting the cancer therapies market growth in Europe. The costs of cancer treatment are also expected to increase, as new and often more expensive treatments are adopted as standards of care. The rise in the number of cancer cases will lead to increased demand for and use of cancer immunotherapy, prompting vendors to develop advanced and upgraded therapies further. These factors are driving the market growth.
The high cost of products is one of the factors challenging the cancer therapies market growth in Europe. Most cancers are incurable and require individual-specific treatments. Therefore, several sequential or combination treatments are given to individuals. The high cost of drug development, right from the preclinical stage to approval, leads to the higher cost of the final cancer drugs. Such factors are negatively impacting the market growth.
Cancer Therapies Market in Europe 2022-2026: Segmentation
By type, the market has been segmented into chemotherapy, targeted therapy, immunotherapy, and others. The chemotherapy segment will have significant market share growth during the forecast period. Chemotherapy is the use of drugs to destroy cancer cells or to stop the growth of rapidly dividing cancer cells in the body. It is often given along with radiation therapy, called chemoradiation therapy, to increase the effectiveness of radiation therapy.
By geography, the market has been segmented into Germany, UK, France, Italy, and Rest of Europe. Rest of Europe will have the highest market share growth during the forecast period.
Find additional highlights related to the market. Download a Free Sample
Cancer Therapies Market in Europe 2022-2026: Vendor Analysis
We provide a detailed analysis of around 25 vendors operating in the cancer therapies market in Europe, including Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, and Pfizer Inc. among others.
Subscribe to our “Lite Plan” billed annually at USD 3000 that enables you to download 3 reports/year and view 3 reports/month.
Cancer Therapies Market in Europe 2022-2026: Key Highlights
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will assist cancer therapies market growth in Europe during the next five years
- Estimation of the cancer therapies market size in Europe and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the cancer therapies market in Europe
- Analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of cancer therapies market vendors in Europe
Related Reports:
Hyperkalemia Drugs Market by Type and Geography – Forecast and Analysis 2022-2026
Cancer Biologics Market by Product and Geography – Forecast and Analysis 2022-2026
| Cancer Therapies Market in Europe Scope | |
| Report Coverage | Details |
| Page number | 120 |
| Base year | 2021 |
| Forecast period | 2022-2026 |
| Growth momentum & CAGR | Accelerate at a CAGR of 7.92% |
| Market growth 2022-2026 | USD 34.71 billion |
| Market structure | Fragmented |
| YoY growth (%) | 6.90 |
| Regional analysis | Germany, UK, France, Italy, and Rest of Europe |
| Performing market contribution | Rest of Europe at 34% |
| Key consumer countries | Germany, UK, France, Italy, and Rest of Europe |
| Competitive landscape | Leading companies, competitive strategies, consumer engagement scope |
| Companies profiled | Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, and Pfizer Inc. |
| Market Dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for the forecast period, |
| Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table Of Contents :
***1. Executive Summary
**1.1 Market Overview
*Exhibit 01: Key Finding 1
*Exhibit 02: Key Finding 2
*Exhibit 03: Key Finding 5
*Exhibit 04: Key Finding 6
*Exhibit 05: Key Finding 7
*Exhibit 06: Key Finding 8
***2. Market Landscape
**2.1 Market ecosystem
*Exhibit 07: Parent market
*Exhibit 08: Market characteristics
**2.2 Value chain analysis
***3. Market Sizing
**3.1 Market definition
*Exhibit 09: Offerings of vendors included in the market definition
**3.2 Market segment analysis
*Exhibit 10: Market segments
**3.3 Market size 2021
**3.4 Market outlook: Forecast for 2021 – 2026
*3.4.1 Estimating growth rates for emerging and high-growth markets
*3.4.2 Estimating growth rates for mature markets
*Exhibit 11: Global – Market size and forecast 2021 – 2026 ($ billion)
*Exhibit 12: Global market: Year-over-year growth 2021 – 2026 (%)
***4. Five Forces Analysis
**4.1 Five Forces Summary
*Exhibit 13: Five forces analysis 2021 & 2026
**4.2 Bargaining power of buyers
*Exhibit 14: Bargaining power of buyers
**4.3 Bargaining power of suppliers
*Exhibit 15: Bargaining power of suppliers
**4.4 Threat of new entrants
*Exhibit 16: Threat of new entrants
**4.5 Threat of substitutes
*Exhibit 17: Threat of substitutes
**4.6 Threat of rivalry
*Exhibit 18: Threat of rivalry
**4.7 Market condition
*Exhibit 19: Market condition – Five forces 2021
***5.Market Segmentation by Type
**5.1 Market segments
*Exhibit 20: Type – Market share 2021-2026 (%)
**5.2 Comparison by Type
*Exhibit 21: Comparison by Type
**5.3 Chemotherapy – Market size and forecast 2021-2026
*Exhibit 22: Chemotherapy – Market size and forecast 2021-2026 ($ billion)
*Exhibit 23: Chemotherapy – Year-over-year growth 2021-2026 (%)
**5.4 Targeted therapy – Market size and forecast 2021-2026
*Exhibit 24: Targeted therapy – Market size and forecast 2021-2026 ($ billion)
*Exhibit 25: Targeted therapy – Year-over-year growth 2021-2026 (%)
**5.5 Immunotherapy – Market size and forecast 2021-2026
*Exhibit 26: Immunotherapy – Market size and forecast 2021-2026 ($ billion)
*Exhibit 27: Immunotherapy – Year-over-year growth 2021-2026 (%)
**5.6 Others – Market size and forecast 2021-2026
*Exhibit 28: Others – Market size and forecast 2021-2026 ($ billion)
*Exhibit 29: Others – Year-over-year growth 2021-2026 (%)
**5.7 Market opportunity by Type
*Exhibit 30: Market opportunity by Type
***6. Customer landscape
**6.1 Overview
*Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
*Exhibit 31: Customer landscape
***7. Geographic Landscape
**7.1 Geographic segmentation
*Exhibit 32: Market share by geography 2021-2026 (%)
**7.2 Geographic comparison
*Exhibit 33: Geographic comparison
**7.3 Germany – Market size and forecast 2021-2026
*Exhibit 34: Germany – Market size and forecast 2021-2026 ($ billion)
*Exhibit 35: Germany – Year-over-year growth 2021-2026 (%)
**7.4 UK – Market size and forecast 2021-2026
*Exhibit 36: UK – Market size and forecast 2021-2026 ($ billion)
*Exhibit 37: UK – Year-over-year growth 2021-2026 (%)
**7.5 France – Market size and forecast 2021-2026
*Exhibit 38: France – Market size and forecast 2021-2026 ($ billion)
*Exhibit 39: France – Year-over-year growth 2021-2026 (%)
**7.6 Italy – Market size and forecast 2021-2026
*Exhibit 40: Italy – Market size and forecast 2021-2026 ($ billion)
*Exhibit 41: Italy – Year-over-year growth 2021-2026 (%)
**7.7 Rest of Europe – Market size and forecast 2021-2026
*Exhibit 42: Rest of Europe – Market size and forecast 2021-2026 ($ billion)
*Exhibit 43: Rest of Europe – Year-over-year growth 2021-2026 (%)
**7.8 Key leading countries
*Exhibit 44: Key leading countries
**7.9 Market opportunity by geography
*Exhibit 45: Market opportunity by geography
***8. Drivers, Challenges, and Trends
**8.1 Market drivers
*8.1.1 Increased prevalence of cancer
*8.1.2 Introduction of combination therapies
*8.1.3 Increasing awareness about effective therapies in patient population
**8.2 Market challenges
*8.2.1 High cost of products
*8.2.2 Side effects associated with available medicines
*8.2.3 Lack of skilled professionals
*Exhibit 46: Impact of drivers and challenges
**8.3 Market trends
*8.3.1 Rise in R&D investment
*8.3.2 Advent of gene therapy
*8.3.3 Personalized therapeutics
***9. Vendor Landscape
**9.1 Overview
*Exhibit 47: Vendor landscape
*The potential for the disruption of the market landscape was moderate in 2020, and its threat is expected to remain unchanged by 2025.
**9.2 Landscape disruption
*Exhibit 48: Landscape disruption
*Exhibit 49: Industry risks
***10. Vendor Analysis
**10.1 Vendors covered
*Exhibit 50: Vendors covered
**10.2 Market positioning of vendors
*Exhibit 51: Market positioning of vendors
*10.3 Amgen Inc.
*Exhibit 52: Amgen Inc. – Overview
*Exhibit 53: Amgen Inc. – Product and service
*Exhibit 54: Amgen Inc. – Key offerings
*Exhibit 55: Amgen Inc. – Key news
**10.4 AstraZeneca Plc
*Exhibit 56: AstraZeneca Plc – Overview
*Exhibit 57: AstraZeneca Plc – Product and service
*Exhibit 58: AstraZeneca Plc – Key offerings
**10.5 Bayer AG
*Exhibit 59: Bayer AG – Overview
*Exhibit 60: Bayer AG – Business segments
*Exhibit 61: Bayer AG – Key offerings
*Exhibit 62: Bayer AG – Segment focus
**10.6 Bristol Myers Squibb Co.
*Exhibit 63: Bristol Myers Squibb Co. – Overview
*Exhibit 64: Bristol Myers Squibb Co. – Product and service
*Exhibit 65: Bristol Myers Squibb Co. – Key offerings
*Exhibit 66: Bristol Myers Squibb Co. – Segment focus
**10.7 Eli Lilly and Co.
*Exhibit 67: Eli Lilly and Co. – Overview
*Exhibit 68: Eli Lilly and Co. – Business segments
*Exhibit 69: Eli Lilly and Co. – Key offerings
*Exhibit 70: Eli Lilly and Co. – Segment focus
*10.8 F. Hoffmann La Roche Ltd.
*Exhibit 71: F. Hoffmann La Roche Ltd. – Overview
*Exhibit 72: F. Hoffmann La Roche Ltd. – Business segments
*Exhibit 73: F. Hoffmann La Roche Ltd. – Key offerings
*Exhibit 74: F. Hoffmann La Roche Ltd. – Segment focus
**10.9 GlaxoSmithKline Plc
*Exhibit 75: GlaxoSmithKline Plc – Overview
*Exhibit 76: GlaxoSmithKline Plc – Product and service
*Exhibit 77: GlaxoSmithKline Plc – Key offerings
*Exhibit 78: GlaxoSmithKline Plc – Segment focus
**10.10 Merck and Co. Inc.
*Exhibit 79: Merck and Co. Inc. – Overview
*Exhibit 80: Merck and Co. Inc. – Business segments
*Exhibit 81: Merck and Co. Inc. – Key offerings
*Exhibit 82: Merck and Co. Inc. – Segment focus
**10.11 Novartis AG
*Exhibit 83: Novartis AG – Overview
*Exhibit 84: Novartis AG – Business segments
*Exhibit 85: Novartis AG – Key offerings
*Exhibit 86: Novartis AG – Segment focus
**10.12 Pfizer Inc.
*Exhibit 87: Pfizer Inc. – Overview
*Exhibit 88: Pfizer Inc. – Product and service
*Exhibit 89: Pfizer Inc. – Key offerings
***11. Appendix
**11.1 Scope of the report
*11.1.1 Market definition
*11.1.2 Objectives
*11.1.3 Notes and Caveats
**11.2 Currency conversion rates for US$
*Exhibit 90: Currency conversion rates for US$
**11.3 Research Methodology
*Exhibit 91: Research Methodology
*Exhibit 92: Validation techniques employed for market sizing
*Exhibit 93: Information sources
**11.4 List of abbreviations
*Exhibit 94: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio